LivaNova (NASDAQ:LIVN) Upgraded at StockNews.com

StockNews.com upgraded shares of LivaNova (NASDAQ:LIVN - Free Report) from a buy rating to a strong-buy rating in a report published on Tuesday.

Several other equities research analysts have also recently commented on LIVN. The Goldman Sachs Group dropped their target price on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Needham & Company LLC restated a "buy" rating and issued a $64.00 price objective on shares of LivaNova in a report on Monday, March 17th. Barclays decreased their target price on LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a research report on Friday, March 7th. Mizuho dropped their price target on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 26th. Finally, Wolfe Research downgraded LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $61.17.

Remove Ads

LivaNova Trading Down 1.2 %

Shares of LIVN traded down $0.49 during mid-day trading on Tuesday, hitting $39.13. 320,232 shares of the company's stock traded hands, compared to its average volume of 609,833. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.13 billion, a P/E ratio of 93.17 and a beta of 1.10. The business's 50-day moving average price is $44.51 and its 200-day moving average price is $48.47. LivaNova has a 1 year low of $36.85 and a 1 year high of $64.48.

Institutional Investors Weigh In On LivaNova

Institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. boosted its stake in LivaNova by 62.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company's stock worth $109,914,000 after purchasing an additional 806,374 shares in the last quarter. Freestone Grove Partners LP purchased a new position in LivaNova in the fourth quarter worth about $23,102,000. Artisan Partners Limited Partnership purchased a new stake in shares of LivaNova during the fourth quarter valued at approximately $21,340,000. The Manufacturers Life Insurance Company increased its position in shares of LivaNova by 163.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company's stock valued at $25,303,000 after acquiring an additional 339,139 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in LivaNova by 79.3% in the 4th quarter. AQR Capital Management LLC now owns 742,180 shares of the company's stock worth $34,214,000 after acquiring an additional 328,313 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.